SEC Form 4 · accession 0001997584-26-000002
Immunome Inc. · IMNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Lechleider
Officer — Chief Medical Officer
Period of report
Jun 25, 2026
Accepted (ET)
Jun 29, 2026 · 4:52 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001472012
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 25, 2026 | M | 55,000 | $8.73 | A | 70,805 | D | |
| Common StockF2 | Jun 25, 2026 | S | 40,580 | $19.56 | D | 30,225 | D | |
| Common StockF3 | Jun 25, 2026 | S | 14,420 | $20.66 | D | 15,805 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F4 | $8.73 | Jun 25, 2026 | M | 55,000 | D | — | Oct 26, 2033 | Common Stock | 55,000 | 345,000 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
- F2The weighted average sale price for the transaction report was $19.56, and the range of prices were between $19.27 and $20.255, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3The weighted average sale price for the transaction report was $20.66, and the range of prices were between $20.275 and $21.02, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F425% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.